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Abstract
Background: Human T cell Leukemia virus type 1 (HTLV-I) is etiologically linked to adult T cell leukemia/lymphoma
(ATL) and an inflammatory neurodegenerative disease called HTLV-I-associated myelopathy or tropical spastic
paraparesis (HAM/TSP). The exact genetic or epigenetic events and/or environmental factors that influence the
development of ATL, or HAM/TSP diseases are largely unknown. The tumor suppressor gene, Fragile Histidine Triad
Diadenosine Triphosphatase (FHIT), is frequently lost in cancer through epigenetic modifications and/or deletion.
FHIT is a tumor suppressor acting as genome caretaker by regulating cellular DNA repair. Indeed, FHIT loss leads to
replicative stress and accumulation of double DNA strand breaks. Therefore, loss of FHIT expression plays a key role
in cellular transformation.
Methods: Here, we studied over 400 samples from HTLV-I-infected individuals with ATL, TSP/HAM, or asymptomatic
carriers (AC) for FHIT loss and expression. We examined the epigenetic status of FHIT through methylation specific
PCR and bisulfite sequencing; and correlated these results to FHIT expression in patient samples.
Results: We found that epigenetic alteration of FHIT is specifically found in chronic and acute ATL but is absent in
asymptomatic HTLV-I carriers and TSP/HAM patients’ samples. Furthermore, the extent of FHIT methylation in ATL
patients was quantitatively comparable in virus-infected and virus non-infected cells. We also found that
longitudinal HTLV-I carriers that progressed to smoldering ATL and descendants of ATL patients harbor FHIT
methylation.
Conclusions: These results suggest that germinal epigenetic mutation of FHIT represents a preexisting mark
predisposing to the development of ATL diseases. These findings have important clinical implications as patients
with acute ATL are rarely cured. Our study suggests an alternative strategy to the current “wait and see approach”
in that early screening of HTLV-I-infected individuals for germinal epimutation of FHIT and early treatment may offer
significant clinical benefits.
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Background
The HTLV-I virus is etiologically linked to a neurode-
generative disease, HTLV-I-associated myelopathy or
tropical spastic paraparesis (TSP/HAM), and adult T-
cell leukemia/lymphoma (ATL), a fatal T-cell leukemia
stemming from infection with the HTLV-I virus [1, 2].
The etiology and pathogenesis of ATL diseases are not
clear but the long latency period of > 20–40 years sug-
gests that ATL disease results from virus-induced accu-
mulation of genomic alterations [3]. The HTLV-I virus
encodes an oncogenic protein, Tax, that plays an essen-
tial role in T-cell transformation. Among its roles, the
HTLV-I Tax oncoprotein provokes DNA replication
fork stalling and collapse, generates DNA double strand
breaks (DSB) in dividing cells, and impairs homologous
recombination (HR) repair of DSBs creating an environ-
ment conducive for the accumulation of genetic alter-
ations [4, 5]. However, the presence of the virus alone or
Tax functions are insufficient for disease progression
since the lifetime cumulative risk of developing ATL is
less than 5%; and most infected individuals remain
asymptomatic. Several reports have described familial
ATL cases [6, 7] which prompted us to hypothesize that
a germinal alteration may predispose HTLV-I-infected
individuals to ATL disease progression.
Studies using different approaches, such as genome-
wide sequencing and transcriptome and methylome ana-
lyses have revealed numerous cellular genes altered in
ATL samples [8]. Risk factors for AC patients to pro-
gress to ATL include higher proviral loads (PVLs), older
age, family history of ATL and oligoclonal or monoclo-
nal expansion of clones [9, 10]. High plasma levels of
soluble tumor necrosis factor receptor 2 (sTNFR2) have
been found in acute ATL, and could be used for diag-
nostic purposes [11]. A group of driver mutations
(PLCG1, PRKCB, CCR4, TP53, and NOTCH1) have also
been found in clonally expanded asymptomatic carrier
patient cells of Afro-Caribbean lineage with high proviral
loads that went on to develop aggressive ATL [12]; while
sub-clonal mutations in the NF-κB/NFAT pathway have
been found in the same geographical region of patients
that relapsed or progressed from an indolent to aggres-
sive ATL [13]. The mutational and transcriptional land-
scape of ATL patients from North America (which are
predominately of Caribbean origin) also displayed simi-
lar mutations with a higher epigenetic mutational rates
in EP300 [14]. Additional epigenetic or histone modifiers
were also mutated; likely making these patients more
susceptible to epigenetic treatment with DNA
methyltransferase inhibitors. In a study focusing on
TSP/HAM patient samples that progressed to ATL dis-
ease, those with a dominant clone and an ATL-like mu-
tational signature went on to develop ATL [15].
Among the genes reported to be altered in a genome-
wide methylome analysis, we selected FHIT as a poten-
tial candidate for an ATL predisposition factor because
of its essential role in preserving genome integrity and
its frequent inactivation in human cancers. The FHIT
gene is found at 3p14. 2, a region with enhanced replica-
tion stress. This location contains the FRA3B gene, the
most common fragile site in the genome that is involved
in cancer induced chromosome rearrangements [16].
Due to FHIT’s location, deletions within FHIT are com-
mon in cancer. FHIT has been described as a tumor
suppressor gene and disruption of one or both FHIT al-
leles leaves cells susceptible to carcinogen induced trans-
formation [17, 18]. Over 50% of cancers show loss of
FHIT expression; and it is believed that this loss is one
of the earliest initiation events in the establishment of
cancers [19]. In fact, reduced FHIT expression has been
suggested to drive initiation of the specific cancer muta-
tional signature [20]. Several observations suggest that
the cumulative effect of Tax expression and lack of
FHIT expression may generate a permissive environ-
ment for cellular transformation. Similar to p53, FHIT is
considered a genome caretaker – with FHIT expression
preventing replication stress and opposing replication
forks stalling and forks collapse, while preventing the ac-
cumulation of DSBs during DNA replication [21, 22].
FHIT also has pro-apoptotic properties, activating cas-
pases − 3, − 8, and – 9 [23, 24]. Consequently, it has
been shown that FHIT-deficient cells are prone to ac-
quire cancer promoting mutations and are more easily
transformed in the presence of DNA damaging agents
[25]. Loss of FHIT expression; therefore, leads to a con-
ducive environment in early neoplastic cells for subse-
quent mutations in known tumor suppressor or
oncogenic genes. It could then be hypothesized that
upon HTLV-I infection, T-cells without FHIT would
then be highly favorable to the viral transformation
properties of Tax. To date, no study has examined the
level or integrity of the FHIT gene in HTLV-I associated
diseases. While loss of FHIT expression can occur due
to chromosome breaks, FHIT is also highly methylated
in solid tumors, such as lung, breast, bladder, prostate,
cervical, esophageal, and hepatocellular cancers [26]. In
hematological malignancies, FHIT methylation has been
seen in some cases of myelodysplastic syndrome (MDS),
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acute myeloid leukemia (AML), and acute lymphoblastic
leukemia (ALL), and chronic myelogenous leukemia
(CML) [27–29]. Given that FHIT is a strong tumor sup-
pressor and considered an early hit in the development
of cancer, we examined the status of FHIT in HTLV-I
associated diseases. We found FHIT was highly methyl-
ated in ATL patient samples, compared to healthy do-
nors or other HTLV-I infected samples. Methylation of
the FHIT gene corresponded to loss of FHIT expression
in ATL patient samples. Notably, we found FHIT was
comparably methylated in infected and non-infected
cells in ATL patient samples. This suggests that loss of




This retrospective cross-sectional study was carried out
using PBMCs collected and immediately frozen. All sam-
ples used here are part of previous studies, for which
these samples were collected after informed consent and
approved by appropriate institutional review boards. Ac-
cording to the revised Shimoyama classification [30],
124 patients had acute ATL, 44 had chronic ATL, 20
had smoldering ATL, and 10 had lymphoma ATL. In
addition, 136 patients had TSP/HAM, 89 patients were
asymptomatic carriers (ACs), and 39 patients were
healthy donors (HDs) not infected with HTLV-1. All
samples were taken from blood, with no tissue biopsy.
HTLV-1 proviral load was quantified for the majority of
samples. The PVLs for all sub-types of ATL, TSP, and
ACs were re-assessed using a standard method to com-
pare HTLV-I PVLs. This was necessary to eliminate any
disparity between patient samples due to the wide range
of geographical areas and therefore different methods of
gDNA extraction, purification, and PVL determination.
In addition, due to the long-term collection of patient
samples over many years, a standard PVL method was
required. Upon arrival in the lab, patient samples were
reassessed for gDNA integrity, diluted to 0.0125 μg/μl,
and sample integrity and normalization was determined
by use of qRT-PCR of GAPDH expression. A standard
curve of pcTax plasmid DNA was used to determine
copy number by qRT-PCR for Tax levels using Taqman
probes; and was mixed with HD gDNA to determine
copy number per cell. To compare the PVLs from differ-
ent sample collections, these single use aliquots of 100
copy Tax DNA were generated, stored at − 80, and run
on every qRT-PCR plate. Tax expression was then amp-
lified from the gDNA of each patient sample and com-
pared to the single-use aliquot of Tax/HD DNA. PVLs
are determined per 400 cells. Patient data is provided in
Table 1. The MT4 cell line, an HTLV-I positive, trans-
formed cell line established from a 50-year-old Japanese
male with ATL [31], was used as control. MT4 cells
were grown in RPMI with 10% FBS.
DNA extraction, bisulfite genomic sequencing and
analysis
Genomic DNA (gDNA) was extracted from samples
using DNAzol (ThermoFisher), and treated with Pro-
teinase K, according to the manufacturer’s instruc-
tions. gDNA was treated with bisulfite using the
MethylCode Bisfulfite Conversion Kit (ThermoFisher)
and equal amounts of bisulfite DNA were used in
methylation specific PCR (MSPCR) reactions. Equal
amounts of PCR product were loaded onto TBE gels
and visualized with SYBR green I nucleic acid stain
(Molecular Probes). Primers used are described in
Suppl 2. Methylation status was determined for each
patient according to MSPCR results. For reference
and to determine methylation status, bisulfite DNA
from an UM and M patient were mixed to create a
gradient for PCR detection (Suppl 1A). In all cases
were MSPCR result was ambiguous, bisulfite genomic
sequencing (BGS) was performed. Briefly, bisulfite
DNA was amplified using specific primers using
nested PCR. PCR products were cut from agarose
gels, DNA was purified using QIAquick Gel Extrac-
tion kits (Qiagen), and ligated into the pGEM-T Easy
Vector kit (Promega). Ligations were transformed into
DH5a bacterial strain and individual colonies were se-
lected for sequencing based on standard blue/white
colony selection methods for miniprep DNA extrac-
tion and subsequent sequencing (example in Suppl
1B). Primers used are described in Table 2. For nail
DNA extraction: clipped fingernail fragments were
placed in an Eppendorf tube, washed in an acid buffer
(pH 4) for 15 min, rinsed with TBE, and then incu-
bated in a 1 M NaOH solution for 4 h. The solution
was removed, and fragments were washed twice with
500ul of TBE, pH 7.5 and incubated overnight at 65C
in presence of proteinase K. Genomic DNA was then
extracted by chloroform phase centrifugation and
ethanol precipitation; and gDNA was treated with bi-
sulfite (as stated above).
mRNA extraction and amplification
PBMC were isolated by ficoll centrifugation and RNA
were extracted by TRIzol (ThermoFisher) lysis reagent,
treated with TURBO DNAse (ThermoFisher), and used
for RNA-to-cDNA amplification (Applied Biosystems).
RNA expression was determined using iTaq Universal
SYBR Green Supermix (Biorad) or iTaq Universal
Probes Supermix (Biorad) with the StepOnePlus real-
time instrument (AppliedBiosystems). Primers are de-
scribed in Supplemental 2.
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Statistics
Odd risk ratios and chi-square statistics were deter-
mined for different HTLV-I diseases (Acute, chronic,
smoldering, and lymphoma ATL) against HD, AC, or
TSP patients for FHIT methylation. Odd risk ratios and
their corresponding p-values and confidence intervals
are provided in Supplemental 3. Chi-square results were
determined using X2 (degrees of freedom, N = sample
size) = chi-square statistic value, p = p value). One-way
ANOVA statistics were determined as needed and were
performed using the Social Science Statistical calculator
using the One-Way ANOVA Calculator, including
turkey HSD. For expression data, significance was deter-
mined using a two-tailed T-test for two independent
means with the formula t((N1–1) + (N2–11)) = the t stat-
istic, with appropriate p-values. Pearson’s correlation co-
efficient and corresponding p-values were performed
using the Social Science Statistical calculator.
CD25 and CD19 cell sorting and FACS analysis
Cell sorting was performed by magnetic bead separation
or cell sorting by FACS. For magnetic bead sorting,
PBMCs were washed in PBS containing 2% FBS and in-
cubated with pre-washed Dynabeads anti-CD25 (Fig. 3)
or anti-CD19 pan B (Fig. 4) magnetic beads (Invitrogen)
for 30 min at 4C. The positive selection fraction was iso-
lated by placing the tube for 2 min in a magnet; and cells
were lysed in DNAzol for DNA extraction and/or RNA-
zol for RNA extraction. For isolation of the negative
fraction, cells were incubated for a second round with
magnetic beads to remove residual CD25+ or CD19+
cells. The suspension was placed in a magnet and un-
bound cells were lysed in DNAzol for DNA extraction.
For cell sorting by FACS, cells were sorted on a 20-
parameter FACSAria (BD) instrument and FACSDiVa
software was used for analysis. Purity was confirmed by
one or both methods: an aliquot was used for FACS ana-
lyses with incubation with one of the following fluores-
cently labeled, anti-human monoclonal antibodies:
PerCP Cy 5.5-CD4 (# 552838), APC-CD19 (HIB19/#555,
415), Alexa 700-CD3 (#561805), PE-CD25 (#555432)
and Aqua Blue LIVE/DEAD Fixable Dead Cell Stain
(Invitrogen) for FACS analyses and/or qRT-PCR for Tax
expression to determine HTLV-I positive cell sorting.
Results
An international collaborative effort was organized to
collect over 400 samples from HTLV-I-infected individ-
uals. To ensure genetic diversity of the tested popula-
tion, samples originated from Asia, Africa, Europe,
South and North America. We performed a comprehen-
sive analysis on FHIT gene methylation and expression
in uncultured peripheral blood mononuclear cells
(PBMC) isolated from healthy volunteer donors (HD),
HTLV-I infected asymptomatic carriers (AC), and
HTLV-I infected individuals diagnosed with tropical
spastic paraparesis/HTLV- I-associated myelopathy pa-
tients (TSP/HAM) and adult T-cell leukemia (ATL). Ex-
tracted genomic DNA was subject to bisulfite treatment
and amplified using methylation-specific polymerase
chain reaction (MSPCR) primers located in intron1 of
the FHIT gene (Fig. 1a). Our results indicated that FHIT
is unmethylated in normal healthy donors as well as in
HTLV-I infected asymptomatic individuals and HTLV-I
infected patients with TSP/HAM disease (Fig. 1a). In
contrast, FHIT was strongly methylated in the majority
of samples isolated from HTLV-I ATL patients (Fig. 1a).
These data suggest that epigenetic modification of FHIT
is characteristic of HTLV-I infected individuals with
ATL disease. To further validate and confirm specificity,
we performed bisulfite genomic sequencing (BGS) amp-
lification of a region encompassing the 5′-end of the
FHIT gene (Fig. 1b). The amplification product was
cloned and for each sample five individual clones were
sequenced. Sub-classification of ATL disease into acute,
chronic, and smoldering subtypes demonstrated strong
FHIT gene methylation in acute and chronic ATL pa-
tient samples, and moderate FHIT gene methylation in
smoldering ATL patient samples (Fig. 1b). Representa-
tive data from these patients is presented (Fig. 1b).
These data confirmed that positive FHIT gene methyla-
tion density results obtained using our MSPCR protocol
are specific, accurate and correctly represent methylated
CpG islands in the FHIT gene.
Having validated our MSPCR protocol, we then per-
formed a large-scale analysis consisting of HD (n = 39),
AC (n = 89), TSP/HAM (n = 136) and ATL (n = 198) pa-
tient samples. To ensure genetic background diversity
and worldwide representation in our analysis, we ob-
tained patient samples that originated from South Amer-
ica, Japan, Africa, Caribbean islands, Europe, and the
United Sates (Table 1 and Suppl 4). Overall, our study
demonstrated that a very high percentage of ATL patient
samples (74%) presented with FHIT methylation. In con-
trast, only 7.35% for TSP, 5.6% for asymptomatic car-
riers, and 5.1% of healthy donor samples displayed FHIT
methylation (Fig. 1c). The reasons underlying disease
progression and whether a patient develops TSP/HAM
and/or ATL are largely unknown. Our results suggest
that methylated FHIT may play a major role in the
pathogenesis of ATL and for the first time, clearly repre-
sents an epigenetic signature that differentiates TSP/
HAM (7.35%) from acute and chronic ATL diseases.
Among patients with ATL disease acute (74.2%) and
chronic (88.6%) ATL patient samples were overwhelm-
ingly represented by FHIT gene methylation, whereas 45
and 20% of smoldering and lymphoma-type ATL patient
samples were found to have methylated FHIT.
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Importantly, all the ATL lymphoma samples analyzed
were collected from PBMC where the presence of ATL
cells is less than 5%. When compared to other viral
lymphomas associated with infection by KSHV, HCV or
EBV, ATL lymphoma patients presented with a higher
proportion of methylated FHIT (Suppl 5); however, the
limited number of samples precludes this from being
statistically significant and will need to be expanded
upon in future studies. Graphical representation and
statistical analyses established that FHIT gene methyla-
tion in acute, chronic, and smoldering ATL subtypes,
was statistically significant when compared to HD or
asymptomatic samples (Fig. 1d). BSG analysis allowed us
to examine approximately 32 individual CpG islands in
the 5′-end of the FHIT gene in ATL patient samples.
For most ATL patient samples, individual CpG islands
Fig. 1 FHIT is highly methylated in ATL but not TSP patient samples and correlates with decreased FHIT expression. a Red and black arrows
represent the amplicon for BGS and MSPCR, respectively of individual CpG islands (blocks). A representation of MSPCR for HDs (n = 10), ACs (n =
10), TSP/HAM (n = 10), and ATL (n = 10) samples are shown. Disease type is marked in columns A-D; while individual patients are marked in rows
A-J. MSPCR amplifying the unmethylated (U) or methylated (M) FHIT gene product are shown; individual patients are noted by brackets. b
Representation of BGS of HDs, ACs, TSP, and ATL patients (ATL-A: acute ATL, ATL-C, chronic ATL, and ATL-S, smoldering ATL). U vs M alleles are
noted by white and black boxes, respectively. Horizontal rows represent sequencing of a single colony. c FHIT methylation in ATL (n = 198), ATL
subtypes, TSP (n = 136), AC (n = 89), and HD (n = 39) from MSPCR. d Statistical analysis of FHIT methylation in HD, AC, and ATL samples. p-values
are determined by Chi-Square test. e Representation of the overall percentage of M CpG islands (n = 32) in FHIT for HD (n = 12), AC (n = 10), TSP
(n = 21), and ATL samples (chronic n = 46, acute n = 25). Results represent the average percentage of CpG islands in the analyzed portion of FHIT
from BGS. The ANOVA f-ratio value is 16.67206, with a p-value of < .00001. Individual post hoc Tukey’s HSD p-values are noted when statistically
significant between groups. f Distinct regions of the FHIT gene are methylated in ATL samples. The results are scored from the percentage of
FHIT gene methylation at an individual CpG island from an average of approximately 20 acute ATL patients. g Quantitative real-time PCR
performed on HDs (n = 38) and mostly acute ATL samples (n = 67) for FHIT gene expression. h Quantitative real-time PCR for FHIT gene
expression in HDs (n = 15), methylated ATL (ATL-M; n = 16), and TSP/HAM (TSP; n = 14) samples. i Quantitative real-time PCR for FHIT gene
expression in unmethylated (n = 7) vs methylated (n = 20) ATL patients. For (g-i), results were normalized to GAPDH expression and represent a
fold change from a HD considered as “1”. p-values were calculated using a two-tailed, unequal variance T-test. FHIT CpG status was determined
by MSPCR
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were almost entirely methylated (Fig. 1e). However,
when we randomly selected ATL patients for sequence
analysis, we found that FHIT gene methylation displayed
three peaks with very strong CpG island methylation
that corresponded to regions within and just outside
exon1 (Fig. 1f). A small drop in CpG island methylation
was found outside exon 1 in the FHIT gene. It is pos-
sible that certain areas within the promoter and first
exon of FHIT have a greater impact on FHIT gene ex-
pression. Further analysis will be required to determine
if distinct areas of methylation are significant for FHIT
expression in ATL disease.
The FHIT gene encompasses the FRA3B locus, a com-
mon fragile site deleted in cancer. In addition to methy-
lation, FHIT inactivation occurs due to loss of
heterozygosity, with a high frequency of deletions in
exon 5, which harbors the FRA3B fragile site, and exon
8, which encompasses the histidine triad [32]. We ana-
lyzed ATL samples with unmethylated or weak methyl-
ated FHIT and found only 1 patient with a deletion of
exon 5, and none with deletions in exon 8, demonstrat-
ing that the majority of unmethylated ATL patients’
sample have an intact FHIT gene, with no loss of FHIT
integrity in these regions (Suppl 6). Examination of
FHIT gene expression demonstrated significant de-
creases in ATL patients compared to HDs (Fig. 1g). HDs
from different continents were included, to better match
HDs to geographically different areas of ATL patient
samples. Several outliers were noted with elevated ex-
pression of the FHIT gene. However, because matched
DNA could not be obtained for all HD and ATL patient
samples, an analysis against FHIT methylation could not
be made. We, therefore, examined FHIT expression with
matched gDNA samples for methylation analysis in HD,
TSP, and ATL samples. FHIT gene methylation strongly
correlated with lower FHIT mRNA expression compared
to TSP patient and HD samples (Fig. 1h); and ATL pa-
tient samples with an unmethylated FHIT gene
expressed lower levels compared to methylated ATL pa-
tient samples (Fig. 1i). Overall, these results clearly dem-
onstrate that the FHIT gene is methylated in the
majority of ATL patient samples, which correlates with
decreased FHIT expression in ATL patient samples.
Increased genome methylation is frequently observed
in cancer cells and genome wide methylation analyses of
ATL patients’ samples has suggested that ATL tumor
cells present with a CpG island methylator phenotype
(CIMP) with increasing methylation in advanced ATL
diseases [33]. On the other hand, evidence of familial
ATL disease suggest the possible existence of a genetic
predisposition marker [6, 7]. FHIT has been reported to
be frequently methylated in tumor cells of various hu-
man cancers. We wanted to determine whether FHIT
methylation occurs in ATL cells only because of ATL
disease progression or if FHIT methylation is a preexist-
ing germinal trait that may predispose some infected in-
dividuals to develop ATL diseases. We first examined
several tumor suppressor genes that are known to be
methylated specifically in ATL cells [34, 35]. MSPCR of
FHIT, SHP1, CDNK1A (p21WAF1/CIP1), and CDNK2A
(p14ARF/p16INK4a) were carried out in the same ATL
patient samples. As expected, the FHIT gene was meth-
ylated in all ATL patient samples, whereas CDKN1A
and CDKN2A displayed much lower gene methylation
(Fig. 2a and b). While SHP1 has been reported to be
methylated in ATL patients [36], our analysis demon-
strated that SHP1 was unmethylated in all ATL patient
samples tested. The discrepancy in SHP1 gene methyla-
tion most likely derives from non-specific, saturat-
ing conditions previously used in the SHP1
methylation PCR reaction [36]. To confirm that our
MSPCR results represented the methylation density
of these genes, we also performed BSG and found
strong FHIT gene methylation in ATL patients
compared to CDKN1A, CDKN2A, and SHP1 (Fig.
2c). Next, we investigated if FHIT methylation was
associated or not with ATL disease progression.
Acute, chronic, and smoldering ATL patient sub-
types all displayed FHIT methylation that was not
statistically different between subtypes (Fig. 2d and
e). However, methylation of the microRNA, miR-
124a, previously shown to be methylated in ATL
cells [37], demonstrated ATL subtype specificity,
whereby acute type ATL had statistically significant
higher miR-124a methylation when compared to
smoldering type ATL (Fig. 2d and e).
ATL disease progression is associated with the expan-
sion of tumor cells through cellular replication resulting
in higher proviral loads [38]. In turn, one may suppose
that increased methylation of FHIT may simply reflect
the fact of higher tumor cells in the samples collected.
However, when we examined the correlation between
FHIT gene methylation status and HTLV-I proviral
loads in acute and chronic ATL patient samples, we
found no correlation (Fig. 3a). Consistent with these re-
sults, we found approximately 20% of ATL lymphoma
patients had methylated FHIT. Since the percentage of
circulating ATL cells is very low in the lymphoma type
(less than 5%), these results strongly suggest that non-
infected PBMC from lymphoma-type ATL carry a meth-
ylated FHIT gene. Altogether, our results suggest that
FHIT gene methylation observed in ATL samples is not
the consequence of CIMP and support the possibility of
a preexisting germinal epimutation.
To demonstrate this hypothesis, we decided to investi-
gate the methylation status of FHIT in ATL patients’
cells not infected with HTLV-I. Circulating ATL cells
are phenotypically characterized by markers CD3+/
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CD4+/CD25+; and CD3+/CD4+/CD25- cells are gener-
ally HTLV-I negative [39, 40]. Three acute, 1 chronic,
and 1 smoldering ATL and five HD patient’s samples
were used for CD4+/CD25- and CD4+/CD25+ cell sort-
ing by FACS. The fraction’s purity was confirmed by
using an aliquot for staining with anti- PE-CD25 conju-
gated antibody and FACS analyses (Fig. 3b). Purity of
our fractionation was further confirmed by real time
quantitative PCR of gDNA extracted from each fraction
(Fig. 3c). As expected, amplification of the HTLV-I pro-
virus sequence was detected in the CD25+ fraction of
ATL samples (Fig. 3c). MSPCR results revealed the
FHIT gene to be strongly and specifically methylated in
both CD25- and CD25+ fractions in ATL samples but
not in HDs (Fig. 3d). For these studies, the Rb gene was
used as a control and expectedly the Rb gene was
unmethylated in all fractions for both ATL and HDs
(Fig. 3d). Next, we examined CD25−/+ fractions for
Fig. 2 FHIT is preferentially methylated compared to known epigenetically regulated tumor suppressors (SHP1, CDKN1A, and CDKN2A) in ATL
patients’ samples. a Representation of global MSPCR methylation patterns in a healthy, non-HTLV-I infected, PBMC, an HTLV-I (+) cell line, and
identical acute ATL (n = 10) patients’ samples for FHIT, SHP1, CDKN1A, and CDKN2A. MSPCR bands amplifying the unmethylated (U) or
methylated (M) product are represented. b The FHIT gene is methylated in acute ATL patients’ samples (n = 25) compared to SHP1, CDKN1A, and
CDKN2A. The overall percentage of unmethylated (blue) or methylated (red) FHIT, SHP1, CDKN1A, and CDKN2A MSPCR products in identical
acute ATL patients’ samples is graphed. c BSG analysis of individual CpG islands in the FHIT, SHP1, CDKN1A, and CDKN2A genes of corresponding
ATL patients. BSG was used to determine the methylation pattern of MT4 (an HTLV-I+ cell line), a HD, and six identical acute ATL patients’
samples (A-1 through A-6). Unmethylated and methylated alleles are noted by white and black boxes, respectively; and each horizontal line
represents a single amplified clone. d The FHIT gene does not show variations in methylation in different clinical subtypes of ATL. BSG
sequencing was used to identify the global BSG methylation pattern of FHIT and miR-124a in eight identical acute ATL patients’ samples (A-7
through A-14), and eight identical smoldering ATL patients’ samples (S23-S30). e Graphical representation of the overall percentage of methylated
(M) CpG islands (n = 31) in the FHIT gene and miR-124 microRNA (n = 16) in acute (ATL-A), chronic (ATL-C), and smoldering (ATL-S) samples from
eight identical ATL patients. Patients are graphed from zero CpG islands methylated (0%) to complete CpG islands methylated (100%) in the
analyzed portion of the FHIT and miR-124a genes. The values plotted represent an average value from sequencing of several BGSs. p-values were
calculated by one-way ANOVA statistical test between the three groups
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FHIT gene methylation by BSG. We found the FHIT
gene to not only be strongly methylated in both fractions
of ATL patient samples, but also that the amount of
CpG islands that were methylated to be almost equal be-
tween the leukemic (CD25+) and non-leukemic (CD25-)
cells (Fig. 3e). These results exclude possible contamin-
ation of the CD25- fraction with few ATL positive cells.
In the event of CD25+ cell contamination, then a
significant percentage of the CpG islands analyzed by
BSG would have been unmethylated in ATL patients’
samples, and this is clearly not the case. To detect equal
CpG island methylation between fractions would require
an approximate 50% contamination level, which is not
supported by the FACS or the real time PCR data. Fur-
thermore, BSG analyses of the CDKN1A gene demon-
strated methylation only in the CD25+ fraction. These
Fig. 3 FHIT methylation is equally represented in both germinal and tumor cells and is independent from HTLV-I proviral load. a HTLV-I proviral
load does not dictate FHIT gene methylation. Proviral loads were determined for acute and chronic ATL patients’ samples (n = 131 M and n = 32
UM) and compared to the epigenetic status of the FHIT gene as determined by MSPCR. p-values were obtained by two-tailed, unequal variance
T-tests. b Effective sorting of ATL and HD PBMCs from patients into CD25- and CD25+ fractions by FACS analysis. 5 HDs and 5 ATL patients were
sorted based on CD25 surface expression. c HTLV-I proviral load confirms effective CD25 sorting of HD and ATL patients’ samples. Proviral load
was determined by quantitative PCR for gDNA isolated from CD25- and CD25+ samples. HTLV-I positive proviral loads were found in CD25+
fractions, compared to CD25-. Non-HTLV-I infected, HDs, served as negative controls. d FHIT CpG island methylation occurs in both tumorigenic
(CD25+) and non-tumorigenic (CD25-) leukemic T-cells from ATL patients’ samples. Five non-HTLV-I infected HDs and five ATL patients’ samples
(3 acute, 1 chronic, and 1 smoldering) were sorted into CD25- and CD25+ fractions. Individual MSPCR bands amplifying the unmethylated (U) or
methylated (M) product are demonstrated. Methylation of CpG islands in the oncogene, Rb, was used as a control to demonstrate the specificity
of the FHIT methylated PCR product. e Representation of global BSG methylation pattern of two HDs (HD-1 through HD-2), three acute ATL
patients (ATL-1 through ATL-3) and one smoldering ATL (ATL-4) patient’s sample. Patient cells were sorted into CD25- and CD25+ fractions, and
gDNA was analyzed for FHIT and CDKN1A gene methylation. Unmethylated and methylated alleles are noted by white and black boxes,
respectively. Circle graphs representing the percentage of methylated CpG islands in the FHIT and CDKN1A genes are shown
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results are consistent with proper cell sorting and with
the fact that CDKN1A is known to be specifically meth-
ylated in ATL cells. All these results further support the
notion that in ATL patients, methylation of FHIT is not
restricted to HTLV-I virus infected transformed ATL
cells but rather methylated FHIT is present as a germi-
nal alteration. Since in vivo HTLV-I-associated clonal
expansion of transformed cells is restricted to CD4+ T
cells [41], we next sorted ATL and HD samples into
CD19+ and CD19- fractions. Interestingly, we found a
similar FHIT gene methylation pattern between CD19+
and CD19- cell fractions in ATL samples tested (Fig. 4a).
This was not the case with SYK gene methylation, pref-
erentially expressed in B cells, whereby the CD19- frac-
tion had significantly higher methylation of the SYK
gene compared to the CD19+ fraction [42]. Once again,
the comparable amount of CpG islands methylated in
CD19- and CD19+ cell fractions support a germinal ori-
gin of methylated FHIT. Finally, we extracted gDNA
from clipped nails of two ATL patients and one HDs
and performed BSG. Results demonstrated FHIT methy-
lation only in ATL patients’ nail samples (Fig. 4b).
A longitudinal approach investigating asymptomatic
carriers that progress to ATL is the best approach to es-
tablish FHIT methylation as a diagnostic marker for
ATL disease. However, obtaining these longitudinal pa-
tient samples is extremely difficult due to the low per-
centage of asymptomatic carriers that develop ATL
(2.5–5% lifetime risk) and the exceptionally long incuba-
tion period to acquire ATL disease (over 20 years) [9]. A
recent study was performed examining the development
of ATL disease in 1218 asymptomatic carriers from 2002
to 2008 that had enrolled in the Japanese Joint Study on
Predisposing Factors of ATL Development (JSPFAD) [9].
During a median follow-up period of 1.0 year, 1.1% of
the participants progressed to ATL disease (n = 14). We
obtained gDNA from 10 patients that progressed to
smoldering ATL. DNA was collected during the
Fig. 4 FHIT gene methylation is present in non-leukemic/non-T-cells in ATL patients’ samples. a FHIT gene methylation occurs in both
tumorigenic (CD19-) and non-tumorigenic, B-cells (CD19+) in ATL patients’ samples. A representation of the global BSG methylation pattern of
two HDs (HD-1 and HD-2) and two acute ATL patients (ATL-1 and ATL-3). Patient cells were sorted into CD19- and CD19+ fractions, and gDNA
was analyzed for FHIT and SYK gene methylation. Unmethylated and methylated alleles are noted by white and black boxes, respectively. Circle
graphs representing the percentage of methylated CpG islands in the FHIT and SYK genes are shown. b The FHIT gene is methylated in total
PBMCs and cells from non-hematologic origin (nails) from the same individuals in ATL patients’ samples. A representation of the global BSG
methylation pattern from total PBMCs and nails derived from the same HD (HD-1), lymphoma ATL (ATL-1), an acute ATL (ATL-3; same patient and
data used for CD25+/in Fig. 3), and an asymptomatic/HTLV-I positive patient from an ATL+ family (see Fig. 5). gDNA corresponding to the same
patient from PBMCs (tumorigenic) and nails were analyzed for FHIT gene methylation. For the acute ATL patient, PBMCs were further sorted into
CD25- and CD25+ fractions. Unmethylated and methylated alleles are noted by white and black boxes, respectively. Circle graphs representing
the percentage of methylated CpG islands in the FHIT and SYK genes are shown
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asymptomatic carrier stage of these patients and FHIT
methylation analyzed and compared to samples from pa-
tients with smoldering ATL (Fig. 5a). We found no stat-
istical difference in samples between smoldering ATL
and asymptomatic carrier samples that will eventually
progress to smoldering type ATL (ANOVA F-ratio =
2.6118, p = 0.12174, Fig. 5b). The proviral load did not
correlate with the level of FHIT CpG methylation in
these samples, nor age of the patient (Fig. 5c and data
not shown). Our data suggests that asymptomatic car-
riers that develop smoldering ATL have levels of FHIT
methylation comparable to patients with smoldering
ATL disease and confirm predictive power of methylated
FHIT for disease progression.
Finally, several studies have implied that ATL disease
may cluster in families [6, 7]. A systemic review of litera-
ture suggests that different family members suffer from
the same HTLV-1 disease and most families include two
to four family members with disease [6]. Studies have
shown that 19% of the variation in DNA methylation
levels are contributed to additive genetic effects, largely
due to genetic variants regulating methylation in a cis or
trans manner [43–45]. Methylation can also be caused
by non-additive genetic effects, such as parent-of-origin
effects (POEs) where one inherited parental allele is re-
sponsible for the observed phenotypic effects, as is the
case with genomic imprinting [43, 46]. If this is the case,
FHIT methylation may be found in family members, ex-
posing children of ATL affected family members to de-
velopment of ATL. We obtained samples from two
families, where at least one mother/father had confirmed
ATL. We then examined FHIT methylation status in
corresponding family members (Fig. 5d). In family A, the
father died from ATL disease; however, we were able to
obtain samples from a sibling, a wife, and three children
that were all asymptomatic carriers for HTLV-I. Examin-
ation of FHIT methylation in all asymptomatic carriers
of the family showed strong FHIT methylation in the
sibling and son, with lower methylation in the 2nd son
and daughter. This is remarkable, given that ACs have
Fig. 5 Longitudinal ACs that progress to Smoldering ATL and descendants of ATL patients harbor FHIT methylation. a FHIT CpG island
methylation occurs in both overt smoldering ATL patients (n = 13) and ACs that progressed to smoldering ATL (n = 10). FHIT methylation was
determined by BGS and unmethylated and methylated alleles are noted by white and black boxes, respectively. Due to the limited number of
smoldering ATL patient samples, some patients are duplicated from previous figures (Figs. 1b and 2d). For progressors, FHIT methylation was
determined at the time the patient was an AC, not when the patient developed ATL. b Graphical representation of the overall percentage of
methylated (M) CpG islands (n = 31) in the FHIT gene in smoldering (ATL-S) samples (n = 13) and ACs that developed smoldering ATL (n = 10).
Patients are graphed from zero CpG islands methylated (0%) to complete CpG islands methylated (100%). The values plotted represent an
average value from sequencing of several BGSs. p-values were calculated by one-way ANOVA statistical test between the two groups. The f-ratio
value is 2.61176. The p-value is 0.12174. c PVL does not correlate with the level of FHIT CpG methylation. PVLs were calculated as a % (as
determined in a previous study [9]). PVL % was plotted against the % CpGs methylated. Pearson’s correlation coefficient and resulting p-value are
indicated. d The primary descendants of two HTLV-I positive, ATL patients harbor methylation of the FHIT gene. The methylation status of the
FHIT gene was determined for the immediate family members of two ATL patients’ samples. Patient samples were analyzed by BGS. Squares and
circles denote male and female patients, respectively. White, grey, and black shapes represent non-HTLV-I infected, HTLV-I positive asymptomatic,
and HTLV-I positive ATL, patients, respectively. For patient one (ATL A), the father, was deceased, and further analysis of the FHIT gene could not
be performed. The BGS for patient B4 is identical to patient “AC carrier” in Fig. 4b
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low FHIT methylation (5.62%). In the second family, the
mother, father, and son all had ATL, while one son was
an AC. Again, all family members demonstrated strong
FHIT methylation, including the AC son. These results
suggest that in ATL families, 1- FHIT methylation is
higher in descendants with methylated FHIT (FHIT
methylation = 100%) than in normal asymptomatic car-
riers (FHIT methylation = 5.62%), 2- children of ATL
parents have strongly methylated FHIT regardless of
whether they are asymptomatic carriers or have ATL, 3-
FHIT methylation may be passed down from parents to
children through additive or non-additive genetic effects.
We were unable to follow the descendants and sibling
long-term. However, our data suggests that they are at a
higher risk of developing ATL in their lifetime due to
the strong correlation between ATL disease and FHIT
methylation presented in Fig. 1.
Discussion
ATL diseases have a dismal prognosis with median sur-
vival times of 8.3 and 10.6 months and a 4-year overall
survival rates of 11 and 16% for the acute and chronic
ATL, respectively [47]. To date, a quick method to pre-
dict the risk of an individual infected with HTLV-I to
developing ATL diseases has been largely undefined, ef-
fectively preventing early treatment. The backbone of
ATL therapy is largely unchanged in the past several de-
cades, with new treatment options including allogeneic
hematopoietic stem-cell transplantation (allo-HSCT) or
therapies such as mogamulizumab (anti-CC chemokine
receptor 4 monoclonal antibody) or lenalidomide (im-
munomodulatory agent) being considered [48]. New
treatment options vary considerably in different geo-
graphical regions, with countries such as Japan using
drug therapies that are only available in the country
(such as mogamulizumab and lenalidomide), while zi-
dovudine (AZT) and interferon-alpha (INF-α) are used
mostly in non-Japanese countries. Overall, asymptomatic
carriers and smoldering ATL are often given the “wait
and see approach”, indicating active monitoring, while
some countries administer AZT/INF-α. Chronic and
acute ATL treatment often involves AZT/INF-α, chemo-
therapy and/or allo-HSCT depending on the country
[30, 48]. Reports suggest that if left untreated indolent
type ATL will progress to the acute type. In fact, ap-
proximately half of the patients with chronic ATL pro-
gress to acute ATL within 18months from diagnosis
and die [49]. While multi-agent chemotherapies may
worsen the prognosis of chronic ATL, when compared
to watch and wait for active monitoring [49], early treat-
ment with anti-retroviral therapy AZT/IFN produces
long-term survival of chronic ATL patients [50]. This
suggests that identifying HTLV-I asymptomatic
individuals that have a high probability of developing
ATL is essential in determining an accurate first line of
therapy.
Our study identifies germinal FHIT methylation as a
signature of ATL disease development that is present in
more than 80% of HTLV-I-infected patients with acute
or chronic ATL. A recent study has shown that the tran-
scriptomic profile of North American ATL is distinct
from Japanese ATL [14]. The fact that FHIT is methyl-
ated in ATL patients across all geographical regions
demonstrates its usefulness as a broad prognostic
marker for the development of ATL disease. The ability
to identify and predict which HTLV-I infected asymp-
tomatic patients have a significantly higher risk to de-
velop ATL will allow initiation of treatment earlier with
greater improvement on patients’ overall survival. A re-
cent study of TSP/HAM patients from Japan suggests
that approximately 3% of TSP/HAM patients develop
ATL [15]. We found approximately 7% of TSP/HAM pa-
tients carry a methylated FHIT allele. While further lon-
gitudinal studies are required, it does open the
possibility that FHIT methylation could also predict
ATL development not only in ACs, but in other HTLV-I
associated diseases. One limitation of our study is that
the age distribution was unknown for all patient samples
provided. Given that the development of ATL occurs in
persons over 40 years of age, it is likely that most of the
ATL patient samples used in this study were older. A
study on age-related progression of FHIT methylation
will need to be conducted in the future. However, FHIT
methylation has not been shown to be dependent upon
patient age or gender in any other cancers [51–53] sug-
gesting this is also the case in ATL. It is also possible,
though doubtful, that virus related factors produced by
HTLV-I-infected cells are responsible for FHIT methyla-
tion. It remains highly unlikely due to several observa-
tions: 1- FHIT methylation was independent of proviral
load, 2- non-infected cells (CD25- and CD19-) harbored
methylated FHIT to the same extend as infected cells
(arguing against the dilution effect), 3- gDNA extracted
from nails was positive for FHIT methylation, and 4- the
low number of FHIT methylated samples in asymptom-
atic carriers and TSP/HAM patients, who are infected
with HTLV-I. We found approximately, 22% of acute
and 11% of chronic ATL patient samples had unmethy-
lated FHIT. Why some patients escape FHIT methyla-
tion is currently unknown. We do know that at least one
UM ATL patient sample carried a deletion in exon 5. In
our study, we only tested exons 4, 5, and 8 in a portion
of the UM ATL patient samples. The FHIT gene com-
prises 10 exons, so it is possible that other portions of
the FHIT gene were deleted or mutated creating early
termination or frameshift. Additionally, FHIT is known
to be affected by allelic loss, homozygous deletions,
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LOH, microsatellite instability, microRNAs, and
lncRNAs [54, 55]. miR-143 and miR-29b have both been
shown to regulate FHIT expression, and may have an
impact in ATL disease [56, 57].
This is also the first study to address the expression of
FHIT in HTLV-I infection and ATL disease. Studies
have shown that loss of FHIT expression can direct a
cell into a more genetically favorable cancer inducing
phenotype. Given the long latency period between
HTLV-I infection and the development of ATL disease,
the loss of FHIT early on would be extremely beneficial.
Besides it roles as a genome caretaker, FHIT has known
roles in apoptosis, attenuating NF-κB and AKT/survivin
signaling pathways, Ras/RhoGTPase, a repressor of the
β-catenin pathway, interacts with the SUMO-1 conjugat-
ing enzyme, Ubc9, and plays a role in the cytoskeleton
[26, 58–60]. These pathways are largely disrupted in ATL
patient samples. While the Tax protein plays a role in some
of these pathways, it is possible that loss of FHIT expression
collaborates or enhances these actions of Tax or other
HTLV-I proteins. Tax is highly immunogenic; therefore,
HTLV-I infected cells carry minimal, but inducible levels of
Tax expression [61]. Loss of FHIT expression would allow a
favorable environment for HTLV-I infected cells to obtain
cancer driver events, in the absence of high levels of Tax ex-
pression. Given that FHIT methylation was only seen in
ATL patient samples, and not asymptomatic or TSP/HAM
patient samples, again confirms its specific role in tumor ini-
tiation and/or maintenance. A recent study demonstrated
that OR-2100, a novel decitabine prodrug, was successful in
killing ATL cells through DNA hypomethylation, indicating
that targeting DNA methylation could be effective in elimin-
ating ATL cells [62]. It is also interesting to note that in our
study less than 3% of healthy donors carry a methylated
FHIT gene. This suggests that there is small amount of the
population that may be susceptible to ATL disease if infected
with HTLV-I. Whether these individuals are suspectable to
other forms of cancer is unknown, but in highly endemic
areas, screening for FHIT status and HTLV-I infection could
allow for early identification of individuals that have a higher
propensity to develop ATL. Also, FHIT methylation could
be developed into a rapid test, which would be extremely
beneficial in screening asymptomatic carriers. This would be
vital for viral treatment options that could stop the cells from
developing enough transformative events to develop ATL.
Conclusion
In summary, we have identified the tumor suppressor
gene, FHIT, as being highly disrupted in ATL disease.
The majority of acute and chronic ATL patient’s cells
carry methylated FHIT, which is present in tumorigenic
and non-tumorigenic cells, and leads to loss of FHIT ex-
pression. This suggests that FHIT may be a
predisposition marker for identification of HTLV-I in-
fected individuals that will progress to ATL disease.
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Additional file 1: Supplemental 1. Development of MSPCR and BGS
analysis for examination of FHIT methylation. (A) MSPCR was used to
determine the FHIT methylation status in patient samples. A standard
was derived by mixing bisulfite treated DNA from a patient with UM FHIT
with bisulfite treated DNA from a patient with M FHIT. Ratios of 100:0,
75:25, 50:50, 25:75, and 0:100 were used in MSPCR for UM and M PCR,
respectively. (B) Example of BSG sequencing of an UM and M patient
sample. Arrows point to distinct CpG islands in the same DNA sequence
of FHIT; demonstrating UM (C to T) or M (C remains) in bisulfite treated
DNA. Supplemental 2. Primers used in FHIT study. Accuprime
(Invitrogen) or Q-solution (Qiagen) was used for FHIT, miR-124a, CDKN1A,
and CDKN2A PCRs. Two PCRS were carried out for FHIT, SHP1, SYK,
CDKN1A, and CDKN2A. BGS PCR conditions were as follow: FHIT BGS: 95–
30″, TD: 61–51–1′, 72–1′ (Touchdown). SHP1 BGS: 95–30″, 64–1′, 72–1′ (35-
40c). SYK BGS: 95–30″, 49–30″, 72–30″ (40c). CDKN1A BGS: 95–30″, TD:
55–45-1′, 72–1′ (Touchdown). CDKN2A BGS: 95–30″, TD: 61–51–1′, 72–1′
(Touchdown). miR-124a BGS: 95–30′, 54–40″, 72–40″ (40c). Supplemental
3. Statistical analysis of HTLV-I diseases for FHIT methylation. Odd risk ra-
tios and chi-square statistics were determined for different HTLV-I dis-
eases (Acute, chronic, smoldering, and lymphoma ATL) against HD, AC, or
TSP patients for FHIT methylation. Odd risk ratios and chi-square statistics
were determined for different HTLV-I diseases (Acute, chronic, smoldering,
and lymphoma ATL) against HD, AC, or TSP patients for FHIT methylation.
Chi-square results were determined using X2 (degrees of freedom, N =
sample size) = chi-square statistic value, p = p value). Supplemental 4.
Geographical distribution of patient samples. Pie diagrams were used to
illustrate the geographical distribution of ATL (acute, chronic, smoldering,
and lymphoma type), TSP/HAM, and ACs. Continent of origin (Asia, Africa,
North America (N.Amer.), South America (S.Amer.), and Europe) was deter-
mined from providers. If the continent of origin was not known at the
time, the samples are marked as “unknown”. Acute ATL (n = 124), chronic
ATL (n = 44), smoldering ATL (n = 20), lymphoma ATL (n = 20), TSP/HAM
(n = 136), and asymptomatic (AC), HTLV-I carriers (n = 89). Supplemental
5. FHIT methylation in viral lymphomas. (A) Representation of BGS of
lymphoma-type ATL patients. U vs M alleles are noted by white and black
boxes, respectively. Horizontal rows represent sequencing of a single col-
ony. (B) FHIT methylation status in viral lymphomas. HTLV-I, ATL-
Bellon et al. Molecular Cancer           (2021) 20:86 Page 12 of 15
lymphoma (n = 10), Kaposi’s sarcoma herpesvirus (human herpesevirus-8)
(KSHV) associated lymphoma (n = 13), Epstein-barr (EBV) associated Hodg-
kin’s lymphoma (HL) (n = 18), and hepatitis C virus (HCV) associated
lymphomas (n = 15). Results were determined by MSPCR of FHIT. Sup-
plemental 6. Deletional Analysis of the FHIT gene in ATL patients. (A)
Chart representing UM (or very weak M) ATL patients for deletional ana-
lysis of the FHIT gene. One patient carried a deletion in exon 5. (B) Repre-
sentation of the PCR bands for exon 4, 5, and 8. In some patients, exon 4
was also amplified. Genomic DNA was used to amplify different FHIT
exons with the following primers: FHIT Exon 4: F-GACTAGGAATCAGAAA
TGAATAATTA, R-GCATGTCAGTCAGGTAACAGGTAAGC; FHIT Exon 5: F-
GCTGTTTTATTGTCCACGTGGAAGCT, R-CTCAGCTATGGTAGTGAAAAGG
TCAA; and FHIT Exon 8: F-GATGCACTGTCATTTCAAAGCACTGG, R-CATATC
TCCATGCAAATATTTACTGTC.
Additional file 2: Supplemental Table 1.
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